Solasia Pharma KK
9SO
Company Profile
Business description
Solasia Pharma KK develops and distributes pharmaceuticals and medical devices relating to malignant tumors. The group consists of the company, consolidated subsidiary Solasia Medical Information Consulting (Shanghai) Co. Ltd., and a one-equity-method affiliate. The company is a specialty pharmaceutical company established with the purpose of developing and selling oncology drugs in Japan and other Asian countries, China, and South Korea, and has a portfolio of pharmaceutical and medical device products.
Contact
2-11-1 Shibakoen
4th Floor, Sumitomo Real Estate Shiba Park Tower
Minato-ku
Tokyo105-0011
JPNT: +81 358438045
Sector
Healthcare
Stock type
Defensive
Industry
Drug Manufacturers - Specialty & Generic
Fiscal Year End
31 December 2026
Employees
179
Stocks News & Analysis
stocks
Long term outlook intact for wide moat income share
Acquisition gains balance traffic headwinds.
stocks
ASX rare earths play looks to expand production
The largest rare-earth producer outside of China acquires competitor to increase production.
stocks
Anthropic’s leaked financials reflect fast growth, but not a $2 trillion valuation
Draft IPO filing shows a company growing faster than its annual results can capture.
Morningstar Investment Ideas
Markets
Index | Last price | Change | % Change |
|---|---|---|---|
| All Ordinaries | 8,894.60 | 8.90 | -0.10% |
| CAC 40 | 7,755.76 | 109.31 | -1.39% |
| DAX 40 | 25,068.36 | 380.83 | -1.50% |
| Dow JONES (US) | 50,984.40 | 536.88 | -1.04% |
| FTSE 100 | 10,449.62 | 92.07 | -0.87% |
| HKSE | 24,130.50 | 150.06 | -0.62% |
| NASDAQ | 27,429.86 | 170.03 | -0.62% |
| Nikkei 225 | 70,035.71 | 648.27 | -0.92% |
| NZX 50 Index | 13,684.04 | 16.08 | -0.12% |
| S&P 500 | 7,777.01 | 41.92 | -0.54% |
| S&P/ASX 200 | 8,727.70 | 8.00 | -0.09% |
| SSE Composite Index | 3,842.19 | 11.74 | 0.31% |